Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

Publikation

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

Wissenschaftlicher Artikel/Review - 26.04.2023

Marzolini Catia, Cavassini Matthias, Braun Dominique Laurent, Hachfeld Anna, Bernasconi Enos, Calmy Alexandra, Schmid Patrick, Battegay Manuel, Elzi Luigia, Swiss HIV Cohort Study SHCS

Zitation

Marzolini C, Cavassini M, Braun D, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Elzi L, Swiss HIV Cohort Study S. Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen. Br J Clin Pharmacol 2023

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Br J Clin Pharmacol 2023

Veröffentlichungsdatum

26.04.2023

eISSN (Online)

1365-2125

Kurzbeschreibung/Zielsetzung

We previously observed that some individuals on HIV boosted protease inhibitor containing regimen do not achieve their lipid targets despite elevated statin concentrations. This study evaluated whether the common single polymorphism c.521T>C in SLCO1B1, associated with reduced statin uptake in the liver, could explain this observation.